Company Overview
Aiforia Technologies is a Finnish-based company that specializes in developing artificial intelligence (AI) solutions for the healthcare industry. The company's primary mission is to utilize AI technology to improve diagnostic accuracy and patient outcomes in various medical specialties, including oncology, neurology, and cardiology.
Aiforia Technologies' core values are centered around innovation, collaboration, and customer satisfaction. The company aims to foster a culture of continuous learning and improvement, while prioritizing the well-being of its patients and partners.
Key Products/Services
Aiforia Technologies offers a range of AI-powered solutions for healthcare professionals, including:
- Digital Pathology: Aiforia's digital pathology platform utilizes AI to analyze medical images and provide accurate diagnoses.
- Artificial Intelligence (AI) Solutions: The company offers a range of AI-powered solutions for various medical specialties, including oncology, neurology, and cardiology.
- Cloud-based Platform: Aiforia's cloud-based platform provides a secure and scalable environment for healthcare professionals to access and share medical images and data.
Aiforia's solutions are designed to improve diagnostic accuracy, reduce errors, and enhance patient outcomes. By leveraging AI technology, the company aims to make high-quality healthcare more accessible and affordable for patients worldwide.
Benefits
The benefits of Aiforia Technologies' solutions include:
- Improved Diagnostic Accuracy: Aiforia's AI-powered solutions can analyze medical images with greater accuracy than human clinicians, reducing errors and improving patient outcomes.
- Enhanced Patient Experience: The company's cloud-based platform provides a secure and scalable environment for healthcare professionals to access and share medical images and data, enhancing the overall patient experience.
- Increased Efficiency: Aiforia's solutions can automate routine tasks, freeing up healthcare professionals to focus on more complex and high-value tasks.
Aiforia Technologies is well-positioned to capitalize on the growing demand for AI-powered healthcare solutions. With a strong focus on innovation, collaboration, and customer satisfaction, the company is poised to make a significant impact in the healthcare industry.
Valuation
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Number of Shares (million) | 25.8 | 26.0 | 28.9 | 33.6 | 37.4 | 37.4 | 37.4 |
| Target Valuation (MEur) | 55.0 | 37.1 | 24.8 | 16.9 | 9.6 | 5.9 | 5.9 |
| Target Price | 2.13 | 1.43 | 0.86 | 0.5 | 0.26 | 0.16 | 0.16 |
| Potential, % | -34.1 | -59.1 | -75.6 | -79.5 | -71.6 | -82.5 | -82.5 |
| Recommendation | Sell | Sell | Sell | Sell | Sell | Sell | Sell |
| MCAP (MEur) | 83.4 | 90.6 | 101.5 | 82.3 | 33.8 | 33.8 | 33.8 |
| Price | 3.23 | 3.49 | 3.51 | 2.45 | 0.9 | 0.9 | 0.9 |
| EV | 61.0 | 82.0 | 97.0 | 80.0 | 38.0 | 52.0 | 65.0 |
| P/S | 32.07 | 37.75 | 35.6 | 23.29 | 12.79 | 9.39 | 8.78 |
| EV/S | 23.61 | 34.36 | 33.87 | 22.63 | 14.55 | 14.37 | 16.86 |
| EV/EBIT | -4.21 | -6.46 | -7.92 | -7.15 | -3.07 | -5.74 | -8.57 |
| P/E | -5.57 | -7.01 | -8.5 | -6.5 | -2.9 | -4.69 | -5.59 |
| P/B | 2.85 | 5.06 | 6.12 | 4.83 | 2.67 | 6.17 | -58.27 |
| P/OCF | -8.86 | -11.1 | -13.01 | -10.85 | -4.83 | -4.75 | -4.79 |
| EV/OCF | -6.52 | -10.1 | -12.37 | -10.54 | -5.49 | -7.27 | -9.2 |
| P/FCF | -5.44 | -6.4 | -7.58 | -5.78 | -2.64 | -2.6 | -2.62 |
| EV/FCF | -4.01 | -5.83 | -7.21 | -5.62 | -3.01 | -3.98 | -5.02 |
Income Statement
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Revenue | 2.6 | 2.4 | 2.9 | 3.5 | 2.6 | 3.6 | 3.8 |
| Rev. Growth, % | 85.7 | -7.7 | 20.8 | 20.7 | -25.7 | 38.5 | 5.6 |
| Ebit | -14.6 | -12.8 | -12.2 | -11.2 | -12.5 | -9.0 | -7.6 |
| Ebit Growth, % | -124.6 | 12.3 | 4.7 | 8.2 | -11.6 | 28.0 | 15.6 |
| Ebit, % | -561.5 | -533.3 | -420.7 | -320.0 | -480.8 | -250.0 | -200.0 |
| Profit | -15.0 | -12.9 | -11.9 | -12.7 | -11.6 | -7.2 | -6.0 |
| EPS | -0.58 | -0.5 | -0.41 | -0.38 | -0.31 | -0.19 | -0.16 |
| Profit Growth, % | -51.5 | 14.0 | 7.8 | -6.7 | 8.7 | 37.9 | 16.7 |
| Profit, % | -576.9 | -537.5 | -410.3 | -362.9 | -446.2 | -200.0 | -157.9 |
Balance Sheet
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Acc. Receivable | 1.6 | 1.0 | 1.2 | 2.2 | 1.4 | 1.2 | 1.2 |
| Cash | 24.7 | 14.0 | 11.5 | 9.5 | 2.6 | -10.6 | -23.8 |
| Equity | 29.3 | 17.9 | 16.6 | 17.1 | 12.7 | 5.5 | -0.6 |
| ROE, % | -51.2 | -72.1 | -71.7 | -74.3 | -91.3 | -130.9 | 1000.0 |
| ROCE, % | -45.6 | -53.9 | -52.7 | -46.1 | -62.5 | -70.4 | -113.6 |
| Net Debt | -22.0 | -8.1 | -4.9 | -2.3 | 4.7 | 17.9 | 31.1 |
| Gearing, % | -75.1 | -45.4 | -29.8 | -13.8 | 36.7 | 327.0 | -5361.6 |
| Equity ratio, % | 82.9 | 63.5 | 58.4 | 58.5 | 47.8 | 22.3 | -3.0 |
| Acc. Payable | 1.0 | 2.2 | 2.7 | 2.9 | 3.1 | 4.0 | 4.5 |
| Total Assets | 35.3 | 28.2 | 28.4 | 29.2 | 26.5 | 24.5 | 19.6 |
| ROA, % | -42.5 | -45.7 | -41.9 | -43.5 | -43.8 | -29.4 | -30.6 |
Cash Flow
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.4 | -8.2 | -7.8 | -7.6 | -7.0 | -7.1 | -7.0 |
| Investment Cash Flow | -5.9 | -6.0 | -5.6 | -6.7 | -5.8 | -5.9 | -5.9 |
| Free Cash Flow | -15.3 | -14.1 | -13.4 | -14.2 | -12.8 | -13.0 | -12.9 |
| OCF/CAPEX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial Cash Flow | 1.9 | 3.5 | 10.9 | 12.3 | 5.9 | -0.3 | -0.3 |
Disclaimer
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
The data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.
Contact: quant@quantfactory.eu